Insured but Still Rationing: The Hidden Cost Crisis Forcing Gout Patients to Shortchange Their Colchicine
Having health insurance in America no longer guarantees affordable access to colchicine—and for the millions of gout patients navigating high copays, unfavorable formulary tier placements, and shrinking pharmacy benefit structures, the financial pressure to stretch or skip doses is both real and medically dangerous. This analysis examines the cost landscape that is quietly undermining treatment outcomes for middle-income patients who believed their coverage had them protected.